Full Year Results 

Consort Medical stifled by Wixela delays

Consort Medical stifled by Wixela delays

Shares in Consort Medical (CSRT) have been in an uptrend through much of 2019, buoyed, in part, by news that the US Food and Drug Administration (FDA) had approved Wixela Hub, a generic respiratory drug made by US-listed pharma group Mylan (US:MYL), which employs one of Consort’s drug delivery systems. The indirect benefits of the FDA decision have yet to be fully realised due to delays in the launch of Mylan Wixela, so revenue at the related Bespak segment was flat on FY2018. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now